{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"title":"Stable disease"},{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"7"}],"title":"Progressive disease"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}],"title":"Not assessed"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Number of patients achieving overall response rate","groups":[{"description":"Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRuxolitinib Phosphate: Given PO","id":"OG000","title":"Diffuse Large B-cell Lymphoma (DLBCL)"},{"description":"Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRuxolitinib Phosphate: Given PO","id":"OG001","title":"Peripheral T-cell Non-Hodgkin Lymphoma (PTCL)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"24 weeks","title":"Overall Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}